Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT06119438 |
Other study ID # |
375/2020 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 1, 2020 |
Est. completion date |
April 1, 2020 |
Study information
Verified date |
November 2023 |
Source |
Mersin Training and Research Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The study included 120 male patients who would undergo a prostate biopsy. Patients were
divided into 3 groups as placebo group (n = 40), Levander group (N = 40), and Frankincense
group (n = 40). Aromatherapy agents were added to the nebulizer at a rate of 2%. Only saline
solution was applied to the placebo group. The nebulizer was prepared and operated in the
room where the prostate biopsy would be performed before the procedure. Patients were taken
to the room 5 minutes before the procedure and the nebulizer was operated during the
procedure. The level of anxiety was evaluated by the State Anxiety Inventory (STAI-I). After
the procedure, the patient was rested and were again filled out the STAI-1 form. After that,
the data of all the patients involved in the study was compared.
Description:
The study was conducted at Mersin University Medical Faculty Hospital Urology Department and
Mersin City Training and Research Hospital Urology Department. The study was designed as a
placebo-controlled prospective double-blind study. Approval was obtained from the Mersin
University Ethics Committee for the study (13.05.2020, 375). All patients who participated
were informed about the study and received written consent. The study included 120 male
patients who would undergo a prostate biopsy. Exclusion criteria were identified as; patients
with pain prior to the procedure (VAS value is non-zero), any respiratory disease (lung
cancer, asthma, bronchitis, chronic obstructive pulmonary disease, etc.), patients using
painkillers in the last 3 hours, patients who were disturbed by the smell of used essential
oils and patients with a known allergy to used essential oils with a history of contact
dermatitis against cosmetic odor. Patients with these characteristics were not included in
the study. During transrectal ultrasound-guided prostate biopsy, periprostatic local
anesthesia was routinely administered to all patients and is routinely performed in all
prostate biopsies performed in the clinic. Patients have filled out STAI-2 (trait index)
forms before the procedure. The STAI clearly distinguishes between the temporary situation of
state anxiety and the more general and long-term quality of trait anxiety. The STAI index has
2 subheadings, STAI-1 (state index) and STAI-2 (trait index), with 40 questions. The scores
of each subscale could range from a minimum of 20 to a maximum of 80. A score of 20-31
reflected mild anxiety, 32-42 below moderate anxiety, 43-53 above moderate anxiety, 54-64
relatively severe anxiety, and 65-75 severe anxiety. Patients were grouped and randomized
according to the STAI-2 (trait index) scores.
Patients were divided into 3 groups placebo group (n = 40), Levander group (N = 40), and
Frankincense group (n = 40). Aromatherapy agents were added to the nebulizer at a rate of 2%.
Only saline solution was applied to the placebo group. The nebulizer was prepared and
operated in the room where the prostate biopsy would be performed before the procedure.
Patients were taken to the room 5 minutes before the procedure and the nebulizer was operated
during the procedure. The level of anxiety was evaluated by the State Anxiety Inventory
(STAI-I). The STAI-1 form was used to determine the transitory emotional state and anxiety
level of the participants before and after the procedure. The interrogation procedures were
carried out by an assistant doctor who had no knowledge about the study. After the procedure,
the patient was rested and again filled out the STAI-1 form. After that, the data of all the
patients involved in the study was compared.